Alloantibody detection method, inspection method, detection reagent, manufacturing method of detection reagent, alloantibody detection kit, and leukemia medicine
The detection of alloantibodies using a DBY protein and HLA class II molecule complex allows for early prediction of cGVHD, addressing the lack of effective detection methods and enabling targeted therapeutic interventions.
Patent Information
- Application Number
- JP2023079282
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-22
Smart Images

Figure 2024163554000001_ABST
Abstract
Description
[Technical field]
[0001] In particular, the present invention relates to a method for detecting an alloantibody of graft-versus-host disease, a test method, a detection reagent, a method for producing a detection reagent, an alloantibody detection kit, and a medicine for leukemia. [Background technology]
[0002] Hematopoietic cell transplantation (HCT), especially allogeneic hematopoietic stem cell transplantation, is the most effective treatment for blood and hematopoietic diseases. However, there is a risk of developing a serious complication called graft-versus-host disease (GVHD). GVHD is a pathological condition caused by donor-derived immune cells viewing the recipient as a foreign body, and is broadly divided into acute GVHD and chronic GVHD (cGVHD) after 100 days (approximately 3 months) after transplantation. Chronic GVHD occurs in 30-70% of cases, but there are concerns that the incidence rate may increase with the diversification of transplantation methods.
[0003] Here, Human Leukocyte Antigen - DR isotype (hereinafter referred to as "HLA-DR") is an antigen classified as Class II of the human major histocompatibility complex (hereinafter referred to as "MHC"). HLA-DR is a glycoprotein dimer consisting of two parts, α and β, and forms a complex with a peptide of about 9 to 30 amino acids in length. HLA-DR constitutes a ligand for the T cell receptor (hereinafter referred to as "TCR"), and is an important antigen related to the compatibility of organ transplants. Furthermore, HLA-DR is present on chromosome 6, region 6p21.31, in the human genome, and its types are known to be highly polymorphic.
[0004] As a conventional technique, Patent Document 1 describes a method for predicting post-transplant prognosis in allogeneic hematopoietic stem cell transplantation even in cases where there is a partial HLA mismatch between the donor and the recipient. In the method described in Patent Document 1, in cases where one or two of eight alleles at four loci of HLA genes HLA-A, HLA-B, HLA-C, and HLA-DRB1 are mismatched between a donor and a recipient in allogeneic hematopoietic stem cell transplantation, and the recipient is a patient other than those with malignant blood diseases (myelodysplastic syndromes, hereinafter referred to as "MDS"), prediction of post-transplant prognosis is assisted using as indicators a single nucleotide polymorphism at the 26th base (rs10925027, C or T) of the base sequence shown in SEQ ID NO: 1 of the NLRP3 gene of the donor or recipient, or a single nucleotide polymorphism at the 26th base (rs4612666, C or T) of the base sequence shown in SEQ ID NO: 2, or a single nucleotide polymorphism in linkage disequilibrium therewith, and the type of primary disease of the recipient.
[0005] On the other hand, a significant risk factor for cGVHD is transplantation from a female donor to a male recipient, which is associated with the appearance of alloantibodies against antigens derived from the Y chromosome. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2018 / 079499 Summary of the Invention [Problem to be solved by the invention]
[0007] However, in the prior art, no method for detecting actual alloantibodies related to the pathogenesis in vivo of cGVHD patients has been established.
[0008] The present invention has been made in view of the above circumstances, and an object of the present invention is to solve the above-mentioned problems. [Means for solving the problem]
[0009] The method for detecting an alloantibody of the present invention is characterized by contacting a sample containing a complex of an alloantigen protein and an HLA class II molecule with a detection reagent, and detecting an alloantibody in the sample that binds to the complex. The method for detecting an alloantibody of the present invention is characterized in that the alloantigen protein is a DBY protein. The method for detecting an alloantibody of the present invention is characterized in that the HLA class II molecule is at least one selected from the group consisting of HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR9, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13, HLA-DR14, HLA-DR15, and HLA-DR16. The method for detecting an alloantibody of the present invention is characterized in that the sample is plasma or serum isolated from a subject. The testing method of the present invention includes a detection step of detecting an alloantibody in the sample by any one of the detection methods described above, and a testing step of testing the possibility of developing chronic graft-versus-host disease based on the detection result of the alloantibody in the detection step, and is characterized in that it tests for the possibility of developing chronic graft-versus-host disease. The testing method of the present invention is characterized in that the detection step is a measurement step of measuring the antibody titer of the alloantibody. The testing method of the present invention is characterized in that in the measuring step, the method for measuring the antibody titer of the alloantibody is flow cytometry. The testing method of the present invention is characterized in that, in the testing step, the measured antibody titer of the alloantibody measured in the measurement step is compared with a standard value, and if the measured value is higher than the standard value, the subject is deemed to be at risk of developing chronic graft-versus-host disease, and the standard value is the measured value for a patient who has undergone allogeneic hematopoietic stem cell transplantation from a male donor to a male recipient, or from a female donor to a female recipient, or from a male donor to a female recipient. The testing method of the present invention is characterized in that the subject is a patient who has undergone allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient. The testing method of the present invention is characterized in that, in transplantation from a female donor to a male recipient, the presence of HLA-DRB1*15:02 as the HLA class II molecule makes it easier for chronic graft-versus-host disease to develop, and that the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes it less likely for chronic graft-versus-host disease to develop. The testing method of the present invention is characterized in that, in transplantation from a male donor to a female recipient, the presence of HLA-DRB1*11:01 as the HLA class II molecule makes it easier to develop chronic graft-versus-host disease, and the presence of HLA-DRB1*08:03 makes it less likely to develop chronic graft-versus-host disease. The testing method of the present invention is characterized by determining that in allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient, the presence of HLA-DRB1*15:02 as an HLA class II allele makes it easier for chronic graft-versus-host disease to develop, while the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes it less likely for chronic graft-versus-host disease to develop. The testing method of the present invention is characterized by determining that in allogeneic hematopoietic stem cell transplantation from a male donor to a female recipient, the presence of HLA-DRB1*11:01 as an HLA class II allele makes it easier to develop chronic graft-versus-host disease, and the presence of HLA-DRB1*08:03 makes it less likely to develop chronic graft-versus-host disease. The method for producing a detection reagent of the present invention is characterized in that the detection reagent is added when detecting the alloantibody in the alloantibody detection method. The method for producing a detection reagent of the present invention is characterized by producing the detection reagent. The alloantibody detection kit of the present invention is characterized by comprising the above-mentioned detection reagent. The pharmaceutical agent for leukemia of the present invention is characterized in that it targets a complex formed by the binding of an alloantigen protein and an HLA class II molecule. Effect of the Invention
[0010] According to the present invention, there is provided an alloantibody detection method that can predict the onset of cGVHD in patients who have undergone allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient before the onset of the cGVHD, by contacting a sample with a detection reagent containing a complex formed by the binding of an alloantigen protein and an HLA class II molecule to detect an alloantibody. [Brief description of the drawings]
[0011] [Figure 1] 1 is a graph showing the cumulative incidence of cGVHD for each allele in an F-to-M cohort according to an embodiment of the present invention. [Diagram 2] 1 is a graph showing the cumulative incidence of aGVHD for each allele in the F-to-M cohort according to an embodiment of the present invention. [Diagram 3] 1 is a graph showing the cumulative incidence of overall cGVHD in male recipients according to donor gender according to an embodiment of the present invention. [Figure 4] 1 is a graph showing the cumulative incidence of cGVHD for each allele in an M-to-M cohort according to an embodiment of the present invention. [Diagram 5] 1 is a graph showing the results of FACS of cell surface and intracellular expression of the HY antigen in an example of the present invention. [Figure 6] 1 is a graph showing the results of FACS of cell surface and intracellular expression of HLA-DR according to an example of the present invention. [Figure 7] 1 is a photograph showing the results of a co-immunoprecipitation assay of protein-protein interaction between full-length DBY and HLA-DR according to an example of the present invention. [Figure 8] 1 shows photographs of IF staining using an anti-HLA-DR antibody and an anti-Myc-tag antibody according to an example of the present invention. [Figure 9] 1 shows a photograph of PLA for visualizing protein-protein interaction between Myc-tagged DBY and HLA-DR according to an embodiment of the present invention. [Figure 10] 1 is a graph showing the results of FACS of cell surface DBY expression in the presence or absence of Ii according to an embodiment of the present invention. [Figure 11] 1 is a graph showing the results of detection of anti-DBY / HLA class II complex antibodies in an example of the present invention. [Figure 12] 1 is a graph showing the cutoff of an anti-DBY / HLA class II complex antibody according to an example of the present invention. [Figure 13] 1 is a graph showing the cumulative incidence of cGVHD depending on the presence or absence of an anti-DBY / HLA class II complex antibody according to an embodiment of the present invention. [Figure 14] 1 is a graph showing the relationship between the titer of an anti-DBY / HLA class II complex antibody according to an example of the present invention and the titer of an anti-DBY antibody. [Figure 15] 1 is a graph showing the MFI of HLA-DR in the analysis of DBY / HLA class II complexes according to an example of the present invention. [Figure 16] 1 is a graph showing the MFI of DBY / HLA class II complexes in an analysis of DBY / HLA class II complexes according to an example of the present invention. [Figure 17] 1 is a table showing in silico calculations of the binding affinity of HLA-DRB1 alleles to DBY epitopes according to an embodiment of the present invention. [Figure 18] 1 is a graph showing MFI for anti-DBY / HLA class II complex antibodies in the analysis of DBY / HLA class II complex in an example of the present invention. [Figure 19] 1 is a graph showing the correlation coefficient between the formation of DBY / HLA class II complexes in an embodiment of the present invention and the affinity of alloantibodies from cGVHD patients that bind to DBY / HLA class II complexes. [Figure 20] 1 is a photograph of HE staining of a skin biopsy sample from a cGVHD patient after F-to-M HCT according to an embodiment of the present invention. [Figure 21] 1 is a photograph of IHC of a skin biopsy sample from a cGVHD patient after F-to-M HCT according to an embodiment of the present invention. [Figure 22]1 shows a photograph of PLA for visualizing protein-protein interactions between DBY and HLA-DR in cGVHD according to an embodiment of the present invention. [Figure 23] 23 is a graph of the PLA signal values of the male versus female patients shown in FIG. 22. [Figure 24] 1 is a photograph of IHC staining of BAFF, a cGVHD biomarker, in an example of the present invention. [Diagram 25] 1 shows photographs of IHC staining of cGVHD biomarkers CXCL9 and CXCL10 according to an embodiment of the present invention. [Figure 26] This is a photograph of IF of CD31 and αSMA in an example of the present invention. [Figure 27] 1 is an IF photograph of C4d according to an embodiment of the present invention. [Figure 28] 1 is a graph showing the results of CDC analysis using an anti-DBY / HLA class II complex antibody according to an example of the present invention. [Figure 29] 1 is a graph showing the results of HLA-DR expression analysis using FACS for leukemia cell lines according to an example of the present invention. [Diagram 30] 1 is a graph showing the results of quantitative qRT-PCR analysis of leukemia cell lines according to an embodiment of the present invention. [Diagram 31] 1 shows a PLA photograph for visualizing colocalization of DBY and HLA-DR in a leukemia cell line according to an embodiment of the present invention. [Diagram 32] 1 shows a PLA photograph for visualizing colocalization of DBY and HLA-DR in blast cells of a leukemia patient according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] <Embodiment Mode> Once chronic graft-versus-host disease (cGVHD) progresses, it often becomes difficult to treat, so early detection and treatment are extremely important. A strong risk factor for cGVHD is allogeneic transplantation from a female donor to a male recipient (F-to-M HCT). This allogeneic transplantation is widely associated with B cell dysregulation characterized by the appearance of alloantibodies against Y chromosome-encoded epitopes (HY antigens). However, to date, no alloantibodies actually involved in the pathogenesis of cGVHD have been identified in the body of cGVHD patients.
[0013] Antibodies to the Y chromosome-encoded H-Y antigen (alloantibody) are known to play an important role in both cGVHD and the graft-versus-leukemia (GVL) effect, and are significantly associated with the maintenance of disease remission. However, HY antigens are intracellular functional proteins involved in transcription and translation, do not have transmembrane domains, and are not released from cells. In other words, all HY antigens are intracellular proteins and do not exit cells by themselves, so they cannot be targeted by antibodies. Furthermore, HY antigens are mainly expressed at the protein level in organs such as the male reproductive organs and heart, which are generally not affected by cGVHD. For this reason, the exact mechanism by which HY antigens appear on the surface of affected organs was previously unknown.
[0014] The inventors have therefore discovered that a complex protein (hereinafter referred to as the "complex") formed by the binding of the DBY protein, one of the HY antigens, with the recipient's HLA class II molecule is expressed on the vascular endothelial cells of the affected organ, and have further demonstrated that the appearance of antibodies against the complex directly contributes to the pathogenesis.
[0015] To explain in more detail, in contrast to acute GVHD (acute Graft Versus Host Disease, hereinafter referred to as "aGVHD"), cGVHD has some clinical characteristics similar to autoimmune diseases such as scleroderma. Autoimmune diseases are closely associated with HLA class II genes. Recently, a new mechanism has been reported in which autoantigens complexed with HLA class II molecules act as potent autoantibody targets in major autoimmune diseases. According to this mechanism, HLA class II molecules form complexes with misfolded proteins in cells and can be transported to the cell surface without fragmentation into peptides. Molecules (complexes) bound to HLA class II molecules of disease-risk alleles are efficiently recognized and targeted by autoantibodies. Transplantation of cells expressing complexes of autoantigens and HLA class II molecules induces autoantibody production in mice. These findings suggest that susceptible HLA class II alleles play an important role in the production of autoantibodies in autoimmune diseases.
[0016] We demonstrated that DBY proteins complexed with HLA class II molecules on vascular endothelium are important targets in the early stages of antibody-mediated cGVHD, which may explain why cGVHD induces the GVL effect. Specifically, we found that HLA class II molecules present full-length HY antigens on the cell surface in cGVHD patients during F-to-M HCT, and that they serve as targets for autoantibodies. In the process, we developed a method for detecting alloantibodies by creating a cell line expressing a complex composed of DBY protein and HLA class II molecules and measuring the alloantibody titer against the complex by contacting the cell line with the patient's plasma three months after allogeneic transplantation.
[0017] When the antibody titer measured by this alloantibody detection method is higher than the cutoff value, the subsequent incidence rate of cGVHD increases significantly, which led to the completion of the present invention. In other words, the alloantibody detection method according to the present embodiment makes it possible to predict the possibility of cGVHD developing in allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient, and thus a method for testing for cGVHD can be realized using the alloantibody detection method according to the present embodiment.
[0018] Furthermore, as shown in the Examples below, the present inventors have demonstrated that the ability of HLA class II molecules to transport DBY and present it to alloantibodies is closely related to the susceptibility of HLA class II alleles to cGVHD. In other words, in certain HLA-DR alleles that have a high ability to present DBY to alloantibodies, DBY specifically colocalizes with HLA class II molecules in the endothelium of skin blood vessels in cGVHD patients and induces complement-dependent cytotoxicity. Therefore, the testing method according to this embodiment also makes it possible to determine the susceptibility or resistance of developing cGVHD due to HLA class II alleles. Furthermore, the present inventors have demonstrated that the complex is expressed in some leukemia cell lines derived from men, and have demonstrated that antibodies targeting this complex can be used as pharmaceuticals. The alloantibody detection method, testing method, detection reagent, method for producing a detection reagent, alloantibody detection kit, and leukemia medicine (medical composition) according to the present embodiment will be described in detail below.
[0019] [Method for detecting alloantibodies] The method for detecting an alloantibody according to this embodiment is characterized in that a sample containing a complex of an alloantigen protein and an HLA class II molecule is contacted with a detection reagent, and an alloantibody in the sample that binds to the complex is detected.
[0020] In this embodiment, the subject for detecting alloantibodies may be a patient who has undergone allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient, and a sample from this subject may be used.
[0021] The alloantigen protein of this embodiment may be primarily an HY antigen, such as DBY, EIF1AY, RPS4Y, UTY, or ZFY protein, which are a group of minor histocompatibility antigens encoded by the male-specific region of the Y chromosome.
[0022] More specifically, the HY antigen according to this embodiment may be, in particular, a DBY protein. The DBY protein is an ATP-dependent RNA helicase encoded by the DDX3Y gene present on the Y chromosome in humans, and is also called DDX3Y. The DBY protein is a DEAD box protein characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD). As mentioned above, the DBY protein is transported onto the cell membrane by binding to HLA-class II molecules in its full length, and can become a target for antibodies.
[0023] On the other hand, in the alloantibody detection method according to the present embodiment, the HLA class II molecule is a transmembrane protein that is usually expressed in macrophages, dendritic cells, and antigen-presenting cells in the B cell wing, and is a major histocompatibility complex (MHC) molecule. The HLA class II molecule has a structure in which an α chain and a β chain are associated, and has the function of presenting peptides, which are fragments of various proteins within the cell, on the cell surface.
[0024] The HLA class II molecule of this embodiment may be at least one selected from the group consisting of HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR9, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13, HLA-DR14, HLA-DR15, and HLA-DR16.
[0025] [Testing method] The testing method of this embodiment includes a detection step of detecting alloantibodies in a sample by the above-mentioned detection method, and a testing step of testing the possibility of developing cGVHD based on the detection results of the alloantibodies in the detection step, and is characterized by testing the possibility of developing cGVHD.
[0026] Among these, the detection step may be a measurement step of measuring the antibody titer of the alloantibody. The antibody titer can be measured using various techniques for detecting antibodies, such as a complement fixation test (hereinafter also referred to as "CF"), a fluorescent labeled antibody method (hereinafter also referred to as "FA"), an enzyme-linked immunosorbent assay (hereinafter also referred to as "ELISA"), a chemiluminescent enzyme immunoassay (hereinafter also referred to as "CLEIA"), or a fluorescence-activated cell sorting (hereinafter simply referred to as flow cytometry or "FACS").
[0027] More specifically, in the measurement step according to this embodiment, it is particularly preferable that the method for measuring the antibody titer of an alloantibody is flow cytometry. The subject sample to be tested may also be plasma or serum isolated from the subject.
[0028] That is, it is possible to measure the antibody titer of an alloantibody that binds to a complex formed by binding an HY antigen such as a DBY protein and an HLA class II molecule using FACS. Specifically, for example, a cell line expressing the above-mentioned complex formed by binding an DBY protein and an HLA class II molecule on the cell surface is used to measure IgG antibodies (alloantibodies) in serum or plasma of a patient after a specific period of time, for example, about 100 days (3 months), has passed after F-to-M HCT. This makes it possible to measure the antibody titer of alloantibodies that cause the pathogenesis of cGVHD.
[0029] The cell line used in this measurement step is not particularly limited as long as the characteristics are understood and the cell line is used by those skilled in the art. Specifically, in the Examples described below, an example using human embryonic kidney cells 293 (hereinafter referred to as "293T" cells) is described. Alternatively, the cell line may be, for example, a leukemia cell line derived from male leukemia. Specifically, a cell line in which DBY is detected by colocalizing with HLA class II molecules in leukemia cells, such as KO52 or THP-1, as described in the Examples below, may be used.
[0030] More specifically, in the testing method according to this embodiment, in the testing process, the measured antibody titer of the alloantibody measured in the measurement process is compared with a reference value, and if the measured value is higher than the reference value, it may be determined that the subject is at a risk of developing cGVHD. The reference value may be a measurement value obtained from a patient who has undergone HCT from a male donor to a male recipient (hereinafter abbreviated as "M-to-M"), or allogeneic transplantation from a female donor to a female recipient (hereinafter abbreviated as "F-to-F"), or allogeneic transplantation from a male donor to a female recipient (hereinafter abbreviated as "M-to-F"). The allogeneic transplantation may be allogeneic hematopoietic stem cell transplantation.
[0031] More specifically, the reference value may be a value based on an antibody titer that allows a statistically significant difference to be tested from the measured expression level. For example, the reference value may be a value that is compared with the expression level of a sample derived from a healthy individual and statistically tested to be, for example, 5% significant (p<0.05). For this test, for example, a T-test, F-test, chi-square test, or other method can be used appropriately depending on the amount of data, the nature of the data, and the like.
[0032] In addition, in the testing method according to the present embodiment, the susceptibility or resistance to the onset of cGVHD may be judged based on the type of HLA-DR allele, because, as shown in the examples below, HLA class II molecules associated with specific alleles transport full-length DBY antigens to the vascular endothelial surface of cGVHD-affected tissues, inducing autoantibodies and becoming an important risk factor for cGVHD after F-to-M HCT.
[0033] Specifically, F-to-M HCT is widely known to be a risk factor for developing cGVHD. Therefore, in the testing method according to this embodiment, it may be determined that in F-to-M HCT, the presence of HLA-DRB1*15:02 as an HLA class II molecule makes cGVHD more likely to develop, whereas the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes it less likely to develop. In other words, in F-to-M HCT, if both the donor and recipient have HLA-DRB1*15:02, it can be determined that the donor should be avoided. On the other hand, in the case of donors and recipients with HLA-DRB1*09:01 and HLA-DRB12:01, the risk of developing cGVHD is low, so the transplant can be expected to be safe.
[0034] Alternatively, in the testing method according to this embodiment, it may be determined that in M-to-F HCT, the presence of HLA-DRB1*11:01 as an HLA class II molecule makes cGVHD more likely to develop, and the presence of HLA-DRB1*08:03 makes cGVHD less likely to develop. In other words, in M-to-F HCT, if both the donor and recipient have HLA-DRB1*11:01, it can be determined that transplants from that donor should be avoided because of the high incidence of cGVHD.On the other hand, if the donor has HLA-DRB1*08:03, the incidence of cGVHD is low, so it can be predicted that transplants can be performed safely.
[0035] Thus, although HLA-matched related donors are the first choice for allogeneic transplantation, in the case of heterosexual donors, more appropriate donor selection can be made based on predicted cGVHD incidence rates.
[0036] The HLA-DR allele types of these male or female recipient subjects may be determined by PCR (Polymerase Chain Reaction), restriction enzyme ladder patterns, genome sequencing, next-generation sequencer sequencing, or the like, in addition to the above-mentioned tests.
[0037] [Detection reagent and method for producing detection reagent] The detection reagent according to this embodiment is characterized in that it is added when detecting an alloantibody in the above-mentioned alloantibody detection method. Such antibody measurement reagents may include, for example, reagents required for CF, FA, ELISA, CLEIA, or flow cytometry, and may also include antibodies for detecting the above-mentioned alloantibodies and other reagents for measuring the above-mentioned HLA-DR types. Furthermore, various enzymes, buffer solutions, washing solutions, dissolving solutions, etc. for detecting each antibody may also be included. In addition, materials and equipment for detecting antibodies by the above-mentioned methods may also be included.
[0038] The method for producing the detection reagent according to this embodiment is characterized by producing the above-mentioned detection reagent. Specifically, the method may include a step of compounding each of the above-mentioned reagents so that they are contained in the concentration and amount required as a detection reagent, a step of preparing materials and equipment, etc. In these manufacturing steps, a person skilled in the art can appropriately manufacture the detection reagent by adjusting, packaging, etc. using various necessary chemical substances, measuring instruments, measuring instruments, etc.
[0039] [Alloantibody detection kit] The alloantibody detection kit according to the embodiment of the present invention is characterized by including the above-mentioned detection reagent. In addition to this detection reagent, the alloantibody detection kit according to this embodiment may further include cells of the above-mentioned cell line, a manual or instructions for the detection kit, and the like. Furthermore, the cGVHD testing kit of this embodiment may include a device for obtaining test results, a computer for analysis, etc. This computer, etc. may be configured as a standalone device, or may be configured using a server on a network. The computer, etc. may include a program for determining test results, processing data, and visualizing the test results, a device and a system equipped with the computer, etc., installed therein. Such devices and systems, etc. can be developed using techniques, methods, etc. common to those skilled in the art. Such devices and systems enable high-throughput testing, facilitating diagnosis of patients.
[0040] [Medicines for cGVHD] The cGVHD medicine (medical composition) according to an embodiment of the present invention is characterized in that it contains a composition that targets a complex formed by the binding of an alloantigen protein and an HLA class II molecule. Specifically, as shown in the Examples below, a complex formed by binding of a DBY protein and an HLA Class II molecule is also expressed on tumor cells of aGVHD and acute leukemia. Therefore, an antibody against this complex can be used as a target for the treatment of leukemia in the future. This antibody may be obtained, for example, by cloning an antibody that induces the GVL effect with an alloantigen against cGVHD using a method by those skilled in the art. Furthermore, not only the antibody itself against this complex, but also truncated antibodies, antibody-like chemical substances, PNA, nucleic acids, compounds corresponding to the recognition site of the antibody, antibodies bound to drugs with cytotoxicity or anticancer activity, and those using DDS (Drug Delivery System) (hereinafter simply referred to as "antibodies, etc.") may be used.
[0041] In recent years, it has been revealed that downregulation of HLA class II expression promotes immune escape of leukemia cells and relapse after allogeneic transplantation. In addition, HY antigens are associated with leukemia relapse in transplantation F-to-M HCT. In other words, leukemia relapse may be associated with inhibition of leukemia recognition by antibodies against the complex of the DBY protein and HLA class II molecule according to this embodiment. Therefore, it is possible to provide a gene therapy-like medicine configured to introduce into leukemia cells a nucleic acid or the like that expresses an HLA class II molecule with an enhanced ability to present a complex with the HY antigen according to this embodiment, particularly DBY or the like. That is, for example, a nucleic acid or the like that can cause a complex of an HY antigen and an HLA class II molecule to be presented may be introduced into leukemia cells to provide a therapeutic medicine. This nucleic acid or the like may contain, for example, a sequence similar to DBY and / or HLA-DRB1*15:02 shown in the examples described below. HLA-DRB1*15:02 may be isoform 1 that is more likely to present the complex.
[0042] Furthermore, for the nucleic acid, etc., various virus vectors, plasmid vectors, carriers containing these, liposomes, DDS, etc. may be used. Furthermore, it is also possible to configure the complex to be presented outside the cells in leukemia cells by using techniques available to those skilled in the art, such as genome editing. In addition, a medicine may be prepared that acts on genes or pathways whose expression is regulated in relation to the formation of complexes bound to HLA class II molecules or extracellular presentation, and configured as a medicine for cGVHD.
[0043] Using these drugs for cGVHD, it will be possible to treat leukemia without bone marrow transplantation or in combination with bone marrow transplantation.
[0044] The cGVHD medicament may contain any pharma- ceutically acceptable carrier, such as a liposome carrier, colloidal gold particles, polypeptide, lipopolysaccharide, polysaccharide, lipid membrane, etc. Among these, it is preferable to use a carrier that improves the expression regulating effect of the functional activity regulator.
[0045] Furthermore, the pharma- ceutically acceptable carrier may contain, for example, physiological saline, an isotonic solution containing glucose or other auxiliary drugs, for example, D-sorbitol, D-mannose, D-mannitol, sodium chloride, etc. Furthermore, it is possible to administer the composition together with a suitable dissolving aid, for example, alcohol, specifically ethanol, polyalcohol, for example, propylene glycol, polyethylene glycol, nonionic surfactant, for example, polysorbate 80(TM), HCO-50, etc. Furthermore, the composition may further contain a suitable excipient, etc.
[0046] The cGVHD medicament of the present embodiment may also contain a suitable pharma- ceutically acceptable carrier to prepare a pharma- ceutically acceptable carrier. The carrier may contain a biocompatible material such as silicone, collagen, gelatin, etc. The carrier may also be provided as an emulsion. Furthermore, the medicament may contain any one or any combination of formulation additives such as diluents, flavorings, preservatives, excipients, disintegrants, lubricants, binders, emulsifiers, plasticizers, etc.
[0047] The administration route of the pharmaceutical composition according to the present invention is not particularly limited, and it can be administered parenterally or orally. Parenteral administration can be, for example, intravenous, intraarterial, subcutaneous, intradermal, intramuscular, or intraperitoneal administration, or direct administration to the kidney or the like. The cGVHD pharmaceutical according to an embodiment of the present invention can be formulated using pharma- ceutical acceptable carriers well known in the art in a dosage form suitable for parenteral or oral administration.
[0048] When the cGVHD drug according to the embodiment of the present invention is used for the above-mentioned treatment, the administration interval and dosage can be appropriately selected and changed depending on various conditions such as the state of the disease and the condition of the subject. The single dose and frequency of administration of the cGVHD medicine according to the embodiment of the present invention can be appropriately selected and changed depending on the purpose of administration, and further on various conditions such as the age and weight of the patient, and the symptoms and severity of the disease. The number of administrations and the duration of administration may be just once, or administration may be once to several times a day for about several weeks, and the condition of the disease may be monitored, and administration may be repeated or repeated depending on the condition.
[0049] In addition, the composition of the present invention can be used in combination with other compositions, etc. The composition of the present invention may be administered simultaneously with the other compositions, or may be administered at intervals, with no particular restriction on the order of administration. In addition, in an embodiment of the present invention, the period during which the disease is improved or alleviated is not particularly limited, but may be temporary improvement or alleviation, or improvement or alleviation for a certain period of time.
[0050] [Treatment method] The cGVHD medicine according to the embodiment of the present invention can also be used for animal therapy to treat diseases similar to cGVHD in animals. The animal is not particularly limited, and broadly includes vertebrates and invertebrates. Vertebrates include fish, amphibians, reptiles, birds, and mammals. Specifically, for example, mammals may be rodents such as mice, rats, ferrets, hamsters, guinea pigs, or rabbits, dogs, cats, sheep, pigs, cows, horses, or non-human transgenic primates. In addition, wild animals include, in addition to mammals, fish, birds including poultry, and reptiles. In addition, crustaceans including shrimp and insects, and other invertebrates such as squids are also broadly included. That is, the cGVHD medicine according to the embodiment of the present invention can be used not only for the treatment of humans, but also for the treatment of various animals and for the promotion of growth in livestock. Furthermore, the cGVHD medicine according to the embodiment may be usable for autoimmune diseases other than cGVHD.
[0051] [Method for identifying HLA-DR alleles that are risk factors for cGVHD] Here, in the testing method according to this embodiment, HLA-DR alleles that are risk factors for cGVHD can be selected by analysis in the following steps. In other words, it will be possible to identify HLA-DR alleles that predict the susceptibility to developing cGVHD in heterosexual transplants involving HLA-matched related donors.
[0052] (Step S1) A database of HLA types is accessed. This database may be provided by, for example, the Japan Society for Hematopoietic Stem Cell Transplantation, as shown in the Examples below. Specifically, it is preferable to use nationwide registry data stratified by the sex of the donor and recipient.
[0053] (Step S2) Select the registered data obtained from the database. This selection is limited to transplants between HLA-compatible related donors to avoid the impact of HLA allele mismatches on cGVHD. This is because in unrelated donor transplants, only the four main HLA items, HLA-A, B, C, and DR, can be measured in insurance medical care in Japan. In other words, even if these four items match, there is a possibility of mismatch due to HLA-DP, DQ, etc., which are not measured.
[0054] (Step S3) Selected registry data will be stratified and further selected by donor and recipient sex.
[0055] (Step S4) Objective: To perform a multivariate analysis of the association between stratified and selected HLA-DR alleles and cGVHD, and to identify specific HLA class II alleles that contribute to susceptibility to cGVHD after transplantation from HLA-related donors.
[0056] By carrying out the analyses such as those in steps S1 to S4 described above, it is possible to determine the susceptibility or resistance of each HLA allele to developing cGVHD as the type of HLA-DR allele. That is, it is possible to identify HLA-DR alleles that are risk factors for cGVHD and use them in the above-mentioned testing method.
[0057] [Effects of the Invention] With the above configuration, the following effects can be obtained. cGVHD is a polymorphic autoimmune and alloimmune disease, and is the main cause of late illness and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation. Once cGVHD progresses, it often becomes intractable, so early detection and treatment are extremely important. However, the target cells and antigens in tissues affected by cGVHD have not yet been elucidated. Furthermore, there have been no cGVHD mouse models that adequately reproduce all of the clinical and pathological characteristics observed in humans. For this reason, it has been difficult to predict the onset of cGVHD, and conventional diagnoses have often been too late.
[0058] In contrast, the alloantibody detection method according to the present embodiment makes it possible to predict the onset of cGVHD before the onset of the disease. That is, it is possible to predict the onset of cGVHD in patients who have undergone allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient before the onset of the disease. This contributes to the early detection and early treatment of cGVHD.
[0059] Furthermore, cGVHD is a multi-organ syndrome with clinical characteristics similar to autoimmune diseases. Therefore, as shown in the Examples below, by focusing on the target of immune cells and understanding the presence of HLA alleles that are disease risks in the pathophysiology of cGVHD and autoimmune diseases, the complex pathology of cGVHD can be understood and contribute to the development of effective new treatments.
[0060] In addition, it has been known that a significant risk factor for cGVHD is transplantation from a female donor to a male recipient, and that this is associated with the appearance of alloantibodies against the HY antigen encoded by the Y chromosome. However, because HY antigens are generally localized intracellularly in the male reproductive organs, it was unclear how they appeared at the organ level. Therefore, the actual alloantibodies involved in the pathogenesis of cGVHD patients in vivo had not been elucidated, and no method for their detection had been established.
[0061] In contrast, in this embodiment, as shown in the examples described below, it has been revealed that antibodies against the complex formed by the binding of the DBY protein encoded by the Y chromosome and the recipient's HLA class II molecule are directly involved in the pathogenesis of cGVHD.
[0062] Therefore, in allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient, if the antibody titer measured by the allogeneic antibody detection method of this embodiment is higher than the standard value, it is possible to predict the high possibility of subsequent onset of cGVHD. This provides important information for determining the treatment plan for allogeneic hematopoietic stem cell transplantation, i.e., the measured values provide data for doctors to determine the prediction of the onset of cGVHD and NRM with high reliability.
[0063] In addition, the involvement of specific HLA-DR alleles in the development of cGVHD has not been reported until now, because no analysis has been conducted stratifying the donor and recipient gender.
[0064] In contrast, the testing method according to the present embodiment allows for testing of a specific HLA-DR allele of a recipient to determine whether the recipient is prone to develop cGVHD. In other words, it is possible to determine whether a specific HLA-DR allele is a risk factor for cGVHD, particularly in allogeneic hematopoietic stem cell transplantation from a donor who is HLA-matched by blood but different in sex. Therefore, the test method of this embodiment can also be used as a test method for preliminary diagnosis for early diagnosis. In other words, the test method of this embodiment can determine the likelihood of developing cGVHD early and accurately. As a result, it is possible to select an appropriate donor, perform early treatment, etc., and improve the therapeutic effect.
[0065] Furthermore, an antibody or the like that targets the complex formed by binding the alloantigen protein of this embodiment and an HLA class II molecule can be used as a medicine for leukemia.
[0066] In the above-described embodiment, an example was described in which a detection step is performed to detect alloantibodies in a sample, and then the type of HLA-DR allele is measured to determine whether a subject is likely or unlikely to develop cGVHD. However, as a test method according to another embodiment of the present invention, it is also possible to judge whether cGVHD is likely to develop or not likely to develop without including a step of detecting an alloantibody. That is, as a test method, it may be determined that in F-to-M HCT, the presence of HLA-DRB1*15:02 as an HLA class II allele makes it likely to develop cGVHD, and that the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes it unlikely to develop. On the other hand, in M-to-F HCT, it may be determined that the presence of HLA-DRB1*11:01 makes cGVHD more likely to develop, whereas the presence of HLA-DRB1*08:03 makes cGVHD less likely to develop.
[0067] Furthermore, the pharmaceutical according to the embodiment of the present invention can be used in combination with other compositions, etc. The composition of the present invention may be administered, sprayed, applied, etc., simultaneously with other compositions. Furthermore, in the above-described embodiment, the sample obtained from the subject is described as being plasma or serum isolated from the subject, but the sample may also be a skin sample or a blood vessel sample obtained by biopsy.
[0068] In addition, the medical composition according to the present embodiment can be used for purposes other than medicine, and can also be used in experiments and models of the mechanism of action in cGVHD in animals. EXAMPLES
[0069] The cGVHD-specific biomarker according to the embodiment of the present invention will be described in more detail below as an example based on a specific experiment. However, this example is merely an example and is not intended to be limiting.
[0070] Materials and Methods (Clinical Data) Clinical data of hematopoietic stem cell transplant recipients were obtained from a Japanese national database (Transplant Registry Unified Management Program, hereafter referred to as "TRUMP") and provided by the Japan Society of Transplantation and Cellular Therapy (hereafter referred to as "JSTCT") and the Japan Data Center for Hematopoietic Cell Transplantation (hereafter referred to as "JDCHCT"). Adult patients (aged ≥18 years) who received their first transplant from an HLA-identical related donor between 2001 and 2019, achieved neutrophil engraftment, and survived for ≥100 days were acquired and included in the selection. Data on HLA-A, -B, -C, and -DR alleles were available for all donors and recipients. Patients without hematologic disorders or with insufficient information on HLA and cGVHD were excluded. To focus on the influence of donor-derived antibodies on the development of cGVHD, patients who did not achieve remission before and after transplantation were also excluded. Myeloablative (MAC) regimens consisted of a total radiation dose of >8 Gy, oral busulfan dose of >9 mg / kg, intravenous busulfan dose of >7.2 mg / kg, or melphalan dose of >140 mg / m 2 24 Grades II–IV aGVHD and cGVHD were diagnosed by the attending physician. This study was approved by the Data Management Committee of TRUMP and the Review Board of Jichi Medical University.
[0071] (human samples) Human samples, plasma (n = 143), skin biopsy specimens (n = 7), and leukemia cells (n = 14), were obtained from the Jichi Medical University Hospital and acquired at the Saitama Medical Center, Jichi Medical University Hospital. The study was approved by the Jichi Medical University Epidemiological Research Bioethics Committee in accordance with the ethical principles stated in the Declaration of Helsinki. Informed consent was obtained from all individuals included in the analysis.
[0072] (cell line) 293T cells (RCB2202), Raji cells (RCB1647), and THP-1 cells (RCB1189) were purchased from RIKEN. HEL (JCRB0062), KasumiA-541 (JCRB1411), KHM-2B (JCRB1394), and KO52 cells (JCRB0123) were obtained from the Japan Research Bioresources Cell Bank. 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (P / S) (Gibco), and GlutaMAX supplement (Gibco). HEL, KHM-2B, Raji, and THP-1 cells were maintained in RPMI1640 medium (Sigma-Aldrich) containing 10% FBS and 1% P / S. KasumiA-541 cells were grown in RPMI1640 medium containing 20% FBS and 1% P / S. KO52 cells were cultured in α-MEM (Gibco) containing 10% FBS and 1% P / S. All cell lines were cultured at 37°C in a 5% CO2 incubator.
[0073] (Transfection of HY antigens and HLA-DR alleles) 293T cells were cultured for 24 hours in a 24-well cell culture plate (Corning). After the cells reached 70-80% confluency, they were transfected with plasmid DNA (full-length HY antigen, HLA-DRA*01:01, each HLA-DRB1 allele, and GFP) using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's instructions. Two days after transfection, the cells were harvested and analyzed by flow cytometry, immunoblot, immunofluorescence staining (hereinafter referred to as "IF"), and in situ Proximity Ligation Assay (hereinafter referred to as "PLA").
[0074] (plasmid) pSI Mammalian Expression Vector was purchased from Promega, and pCAG-GFP was purchased from Addgene. Full-length cDNAs of DBY (isoform 1), EIFA1Y, RPS4Y1, UTY, and ZFY were obtained from Horizon. Because there are no commercially available anti-HY antibodies suitable for flow cytometry, these cDNAs were cloned by PCR and a FLAG tag (DYKDDDDK) was added to the N-terminus and a Myc tag (EQKLISED) was added to the C-terminus. These cDNAs were ligated to the EcoRI and NotI sites of the pSI vector using a DNA Ligation kit (Takara Bio). pSI-FLAGDBY-Myc, pSI-FLAG-EIFA1Y-Myc, pSI-FLAG-RPS4Y1-Myc, pSI-FLAG-UTY-Myc, and pSI-FLAG-ZFY-Myc were then created. DBY isoforms 2 and 3 were cloned from In-FLAG-DBY(isoform 1)-Myc using the In-Fusion HD Cloning Kit. The gene constructs for HLA-DRA1*01:01, HLA-DRB1*15:01, HLA-DQA1*01:01, HLA-DQB1*05:01, and invariant chain were purchased from Eurofins Genomics. The sequences of HLA-DRB1 alleles were confirmed using the IMGT / HLA database (https: / / www.ebi.ac.uk / ipd / imgt / hla / ). In the TRUMP F-to-M cohort, HLA-DRB1 alleles from 5 or more patients were generated from HLA-DRB1*15:01 using the In-Fusion HD Cloning Kit and KOD-Plus-Mutagenesis Kit (Toyobo). The amplified fragments of each of these HLA-DRB1 and invariant chains were transformed into pSI The expression plasmids were transformed into Escherichia coli DH5α (Takara Bio) and cultured at 37° C. in LB broth (Sigma-Aldrich) supplemented with ampicillin (Sigma-Aldrich).These plasmids were prepared using NucleoBond Xtra Maxi (Takara Bio) according to the manufacturer's instructions.
[0075] (Flow cytometry, FACS) Transfected cells were incubated with Human BD Fc block (BD Biosciences) to block non-specific antibody binding. After blocking, dead cells were labeled with FVD780 (eBioscience). Transfected cells were then incubated with specific antibodies for 30 min. For intracellular staining, a transcription factor buffer set (BD Biosciences) was used according to the manufacturer's protocol. Stained cells were analyzed using a BD LSRFortessa™ X-20 (BD Biosciences) and data were analyzed using FlowJo software (Tomy Digital Biology). The antibodies used for flow cytometry analysis are as follows: APC anti-human HLA-DR antibody (L243, BioLegend), APC mouse IgG2a, κ isotype Ctrl antibody (MOPC-173, BioLegend), APC anti-human HLA-DQ antibody (SK10, eBioscience), and PE anti-DYKDDDDK tag antibody (L5, BioLegend).
[0076] (Co-immunoprecipitation and Western blot analysis) Co-immunoprecipitation assay (Co-IP) was performed using Dynabeads Co-Immunoprecipitation kit (VERITAS) according to the manufacturer's instructions. Briefly, Dynabeads M-270 Epoxy was coupled with anti-HLA-DR antibody (HL40, Thermo Fisher Scientific) or anti-DYKDDK-Tag antibody (L5, BioLegend) for 24 hours at 37°C. Transfected cells were lysed on ice for 15 minutes with the included extraction buffer containing 100mM NaCl and 0.2% phenylmethylsulfonyl fluoride protease inhibitor. Antibody-bound Dynabeads M-270 Epoxy was mixed with the lysate for 30 minutes at 4°C. After incubation, the proteins bound to the beads were eluted with the included elution buffer. After elution, the sample proteins were mixed with 2x Laemmli sample buffer (Bio-Rad Laboratories) containing 5% β-mercaptoethanol and denatured by boiling at 98°C for 5 min. The mixture was loaded onto 4%-20% Mini-PROTEAN TGX Precast Protein gels (Bio-Rad Laboratories) and transferred using the iBlot Dry Blotting System (Thermo Fisher Scientific). The membrane was blocked with 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20 for 1 h. After blocking, the membrane was incubated with primary antibody for 1 h at room temperature (25°C, RT), then with secondary antibody for 1 h at RT.The following antibodies were used for Western blot analysis: anti-DYKDDK-tag antibody (2368, Cell Signaling Technology), anti-Myc-tag antibody (ab9106, Abcam), anti-HLA-DR antibody (HL-40, Thermo Fisher Scientific), anti-rabbit IgG, HRP-conjugated antibody (Cell Signaling Technology), goat anti-mouse IgG (H+L) secondary antibody, HRP (Thermo Fisher Scientific). Immunoreactive bands were detected using SuperSignal chemiluminescent substrate (Thermo Fisher Scientific).
[0077] (Analysis of antibodies against DBY / HLA class II complex) Full-length DBY, HLA-DRA*01:01, each HLA-DRB1 allele, and GFP, or HLA-DRA*01:01, each HLA-DRB1 allele, and GFP were transfected into 293T cells. The transfected cells were washed twice with Hanks' Balanced Salt Solution (Thermo Fisher Scientific) containing 0.1% bovine serum albumin. After dead cell staining and FC blocking, the transfected cells were incubated with patient plasma diluted 1:50 on ice for 1 h, followed by labeling with APC-goat anti-human IgG (Jackson Immuno Research) diluted 1:50 for 30 min at RT. The stained cells were then washed twice and analyzed by flow cytometry. The anti-DBY / HLA class II complex antibody titer was calculated by subtracting the MFI of IgG binding to GFP-positive cells transfected with HLA-DRB1*15:02 alone from the MFI of IgG binding to GFP-positive cells transfected with DBY and HLA-DRB1*15:02.
[0078] (Enzyme-linked immunosorbent assay for detection of DBY antibodies in plasma) 96-well flat-bottom plates (Sumitomo Bakelite) were coated with 50 μL of 50 ng / μL DBY protein (MyBioSource) in 50 mM carbonate-bicarbonate buffer and incubated overnight at 4°C. After incubation, the plates were blocked with 200 μL of 5% nonfat milk in phosphate-buffered saline (PBS) and 0.02% Tween for 1 h at 37°C. After washing, the plates were incubated with patient plasma diluted 1:50 in 100 μL of 5% nonfat milk in PBS-0.02% Tween for 1 h at 37°C. The plates were then incubated with peroxidase goat anti-human IgG antibody (Jackson Immuno Research) diluted 1:1000 in 5% nonfat milk in PBS and 0.02% Tween for 30 min at 37°C. Finally, 100 μL of SureBlue® TMB Microwell Peroxidase Substrate (LGC Clinical Diagnostics) was added to the plate, and the reaction was stopped using 100 μL of TMB Stop solution (LGC Clinical Diagnostics). Then, the absorbance at 450 nm was measured using Spark (TECAN) with a reference wavelength of 620 nm. The specific binding of plasma IgG to DBY was determined by subtracting the OD value of the control from the OD value of DBY coated with 50 mM bicarbonate buffer.
[0079] (Effect of different HLA-DRB1 alleles on expression levels of DBY / HLA class II complexes and antibody binding to DBY / HLA class II complexes) Full-length HY, HLA-DRA*01:01, each HLA-DRB1 allele, and GFP were transfected into 293T cells. The expression levels of HY antigen on the cell surface were compared by flow cytometry. Next, autoantibody binding to the DBY / HLA class II complex in each HLA-DRB1 allele was analyzed using plasma collected from a male cGVHD patient 3 months after allogeneic transplantation. Finally, the association between the amount of DBY / HLA class II complex and antibodies binding to DBY / HLA class II complex was evaluated using the Pearson product-moment correlation coefficient.
[0080] (CDC assay) The transfected 293T cells were harvested and washed twice with DMEM containing 10% FBS. After washing, 1 × 10 cells were cultured in 100 μL of DMEM. 6 The cells were incubated with IgG purified from the plasma of a male cGVHD patient, containing anti-DBY / HLA class II complex antibodies, using a spin-column-based antibody purification kit (Protein G) (Cosmo Bio). After 1 h of incubation at 4°C, the cells were washed twice and incubated with standard rabbit complement diluted 1:6 (Cedarlane Laboratories) for 1 h at 37°C. Finally, dead cells were stained with FVD780 and analyzed by flow cytometry.
[0081] (IF) Cells were fixed with 4% paraformaldehyde for 15 min on ice. Nonspecific sites were then blocked with 5% donkey serum in PBS for 1 h at RT. Cells were then incubated with anti-HLA-DR antibody (HL-40, Thermo Fisher Scientific) and anti-Myc-tag antibody (ab9106, Abcam) for 1 h at RT, and treated with goat anti-mouse IgG H&L (Alexa Fluor® 594) preadsorbate (Abcam) and goat anti-rabbit IgG H&L (Alexa Fluor® 488) preadsorbate (Abcam) for 30 min at RT. Nuclei were counterstained with DAPI (PerkinElmer) and images were obtained using an Olympus BX63 microscope (Olympus). Images were processed using Fiji Image J Software (Fujifilm).
[0082] (in situ PLA) PLA was performed using the Duolink in Situ Red Starter kit (Sigma-Aldrich) according to the manufacturer's instructions. Anti-HLA-DR (HL-40, Thermo Fisher Scientific) and anti-Myc-tag (ab9106, Abcam) antibodies were used for transfected 293T cells, and anti-HLA-DR (ERP3692, Abcam) and anti-DBY (B4, Santa Cruz Biotechnology) antibodies were used for formalin-fixed paraffin-embedded (FFPE) sections, human leukemia cell lines, and patient-derived leukemia cells.
[0083] (Histopathological evaluation) FFPE sections of skin biopsy samples were obtained from patients with cGVHD. Healthy skin biopsy samples were purchased from US Biomax and OriGene. Sections were deparaffinized using xylene and dehydrated in a graded ethanol series. Antigen retrieval was performed using target retrieval solution (Dako) at 121°C for 20 min using an autoclave. Hematoxylin-eosin staining was performed using Mayer's Hematoxylin solution (Fujifilm) and Eosin Y (Fujifilm). For IHC, sections after antigen retrieval were treated with 3% hydrogen peroxide for 15 min at RT, blocked with 2% donkey serum in PBS for 30 min at RT, and analyzed using an Avidin / Biotin Block Kit (Vector Laboratory). Sections were then incubated with primary antibodies for 1 h at RT and corresponding secondary antibodies for 30 min at RT. After incubation with secondary antibodies, the VECTASTAIN ABC standard kit (Vector Laboratory) was used according to the manufacturer's instructions. Finally, immunoreactivity was visualized using a peroxidase staining DAB kit (Brown Stain) (Nacalai Tesque). For IF, sections that had undergone antigen retrieval were used. Sections were incubated with primary antibodies for 1 h at 37°C, followed by incubation with secondary antibodies for 30 min at RT. Nuclei were counterstained with DAPI (PerkinElmer).The primary antibodies were anti-DDX3 antibody (C4, Santa Cruz Biotechnology), anti-HLA-DR antibody (HL-40, Thermo Fisher Scientific), α-SMA antibody (ab5694, Abcam), anti-CD31 antibody (H-3, Santa Cruz Biotechnology), anti-BAFF antibody (AF124, R&D Systems), anti-CXCL9 antibody (A-9, Santa Cruz Biotechnology), anti-CXCL10 antibody (1, Santa Cruz Biotechnology), and anti-C4d antibody (ab8724, Abcam). The secondary antibodies were biotinylated horse anti-mouse IgG antibody (H+L) (Vector Laboratory), biotinylated goat anti-rabbit IgG antibody (H+L) (Vector Laboratory), horse antigoat IgG antibody (H+L), biotinylated (Vector Laboratory), and goat The antibodies contained antimouse IgG H&L (Alexa Fluor (registered trademark) 594) preadsorbed (Abeam), and goat antirabbit IgG H&L (Alexa Fluor (registered trademark) 488) preadsorbed (Abeam).
[0084] (qRT-PCR) RNeasy Micro Kit (QIAGEN) was used according to the manufacturer's protocol to separate 5 × 10 4 Total RNA was isolated from leukemia cells. The isolated RNA was then reverse transcribed using superscript IV VILO master mix (Thermo Fisher Scientific). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using QuantiNova SYBR Green PCR Kit (QIAGEN) according to the manufacturer's instructions. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control (comparative example).
[0085] The primers used are as follows and in the attached sequence listing: DBY primer F: 5′-CGTGCTTCTCTTGACCCTGTA-3′ …… SEQ ID NO: (1) DBY primer R: 5′-CCTTGCTCGCTGTACTTGC-3′ …… SEQ ID NO: (2) GAPDH primer F: 5′-GGATTTGTCGTATTGGG3′ …… SEQ ID NO: (3) GAPDH primer R: 5′-GGAAGATGTGATGGATT-3′ …… SEQ ID NO: (4)
[0086] (Wright-Giemsa staining) BM smears were stained with Wright's solution and Giemsa solution (Muto Pure Chemicals).
[0087] (Peptide binding affinity prediction using NetMHCIIpan 4.0) To measure the binding affinity of DBY to each HLA class II allele, NetMHCIIpan 4.0 was used. This system uses an artificial neural network-based alignment method to predict the outcome of peptide binding assays in silico. The peptide length was assumed to be a default of 15 amino acids. The %rank values of the binding affinity of DBY to each HLA-DRB1 allele were compared. A rank value of less than 1.0 was defined as a strong binder.
[0088] (statistical analysis) The cumulative incidence of aGVHD and cGVHD was measured from the time of transplantation to the occurrence of aGVHD and cGVHD, without relapse or death as competing risks. The cumulative incidence of aGVHD and cGVHD was evaluated by the method of Gray. Multivariate analysis was performed using the Fine-Gray method. Patient age (linear), performance status, conditioning regimen, stem cell source, GVHD prophylaxis, year of transplantation, and each HLA-DRB1 allele were included in the multivariate analysis. All statistical analyses were performed using EZR (version 1.55, Jichi Medical University Saitama Medical Center). In vitro analyses were performed using Prism 7.0 software (GraphPad Publishing). For comparison of the means of the two groups, unpaired two-tailed Student's t test in Prism 7.0 was used. In all figures, error bars represent the standard deviation of the mean. All p values <0.05 indicate statistical significance.
[0089] 〔result〕 HLA class II alleles influence the development of cGVHD after allogeneic transplantation in male recipients from HLA-identical female related donors. The present inventors first investigated whether HLA class II alleles affect the occurrence of cGVHD in F-to-M HCT using a Japanese nationwide database. The clinical characteristics of the male patients who received transplants from HLA-identical female related donors (hereafter referred to as the "F-to-M cohort") are shown in Table 1 below:
[0090] [Table 1]
[0091] In Table 1, the F-to-M cohort was analyzed to exclude the potential effect of HLA mismatch on cGVHD. A total of 768 patients (n=768) were evaluated. There were 245 bone marrow (BM) transplants, 522 peripheral blood stem cell (PBSC) transplants, and 1 BM+PBSC transplant. Among the patients, 64.6% were diagnosed with leukemia, 77.9% were administered cyclosporine-based GVHD prophylaxis, and 71.2% received concomitant myeloablative conditioning (MAC regimen).
[0092] Next, the inventors performed a multivariate analysis of the cumulative risk of cGVHD onset in the above-mentioned F-to-M cohort (n=768). Specifically, the effect of HLA-DR alleles (HLA-DRB1 alleles) present at a frequency of 5% or more on the onset of cGVHD was evaluated. The effect of each HLA-DR allele on the onset of cGVHD was calculated using the Fine-Gray method. The results of this analysis are shown in Table 2 below:
[0093] [Table 2]
[0094] (The impact of HLA-DRB1 alleles on the development of cGVHD) As shown in Table 2, the risk of developing cGVHD differed according to the HLA-DRB1 allele. In multivariate analysis, the HLA-DRB1*15:02 positive group had an increased incidence and was significantly associated with an increased risk of cGVHD. The hazard ratio (HR) for this group was 1.28, with a 95% confidence interval (CI) of 1.03 to 1.58, P = 0.025. Conversely, HLA-DRB1*09:01 positivity was significantly associated with a reduced risk of cGVHD (HR 0.74, 95% CI 0.59-0.93, P = 0.010). Additionally, the HLA-DRB1*12:01 positive group was at the borderline of statistical significance: HR for this group was 0.63, 95% CI 0.39-1.01, P = 0.053.
[0095] Actual incidence rates were calculated for these alleles in the F-to-M cohort. The cumulative incidence of cGVHD in this F-to-M cohort is shown in Figure 1. In each graph, the horizontal axis indicates the number of years since transplantation, and the vertical axis indicates the cumulative incidence of cGVHD. Both were compared using Gray's test.
[0096] Figure 1(a) shows the results of comparing HLA-DRB1*15:02 positive (light line) and negative (dark line) patients. The HLA-DRB1*15:02 positive group had a higher cumulative incidence of cGVHD than the HLA-DRB1*15:02 negative group; specifically, 55.1% (95% CI 47.2%-62.3%) vs. 46.6% (95% CI 42.5%-50.5%) at 1 year, P=0.035.
[0097] Figure 1(b) shows the results of comparing HLA-DRB1*09:01 positive (light line) and negative (dark line) patients. The HLA-DRB1*09:01 positive group had a lower cumulative incidence of cGVHD compared with the HLA-DRB1*09:01 negative group; specifically, 40.4% (95%CI 34.0%-46.7%) vs. 51.8% (95%CI 47.5%-56.0%) at 1 year, P=0.009.
[0098] Figure 1(c) shows the results of comparing HLA-DRB1*12:01 positive (light line) and negative (dark line) patients. The HLA-DRB1*12:01 positive group showed a lower cumulative incidence of cGVHD compared with the HLA-DRB1*12:01 negative group. Specifically, at 1 year, the incidence was 34.8% (95% CI 21.3%-48.6%) vs. 49.3% (95% CI 45.6%-52.9%), P=0.045.
[0099] In summary, HLA-DRB1*15:02, HLA-DRB1*09:01, and HLA-DRB1*12:01 were associated with cGVHD in the F-to-M cohort. Specifically, HLA-DRB1*15:02 increased the incidence of cGVHD in the F-to-M cohort. On the other hand, HLA-DRB1*09:01 and HLA-DRB1*12:01 reduced the incidence of cGVHD.
[0100] Figure 2 shows the cumulative incidence of acute GVHD (hereinafter referred to as "aGVHD") in the F-to-M cohort. In each graph, the horizontal axis shows the number of days since transplantation, and the vertical axis shows the cumulative incidence of cGVHD. Both were compared using the Gray test, as in Figure 1.
[0101] According to Figure 2(a), although aGVHD was the major risk factor for cGVHD, HLA-DRB1*15:02 did not differ between the positive and negative groups in the cumulative incidence of grade II-IV aGVHD, specifically, 34.5% (95% CI 27.4%-41.8%) vs. 34.7% (95% CI 30.9%-38.6%) at 100 days, P = 0.795.
[0102] Figure 2(b) shows that HLA-DRB1*09:01 did not significantly affect aGVHD between the positive and negative groups, specifically, 32.2% (95% CI 26.2%-38.3%) vs. 35.8% (95% CI 31.7%-39.8%) at 100 days, P = 0.276.
[0103] Figure 2(c) shows that HLA-DRB1*12:01 did not significantly affect aGVHD between the positive and negative groups, specifically, 37.0% (95% CI 23.2%-50.8%) vs. 34.5% (95% CI 31.1%-38.0%) at 100 days, P = 0.522.
[0104] In summary, HLA-DRB1*15:02, HLA-DRB1*09:01, and HLA-DRB1*12:01 had no effect on the development of aGVHD. These results suggested that HLA-DRB1*15:02, HLA-DRB1*09:01, and HLA-DRB1*12:01 are involved in the development of cGVHD through an aGVHD-independent mechanism.
[0105] Next, similar analyses were performed on male recipients from HLA-identical male related donors (hereinafter referred to as the "M-to-M cohort"), female recipients from female donors (hereinafter referred to as the "F-to-F cohort"), and female recipients from male donors (hereinafter referred to as the "M-to-F cohort").
[0106] First, the clinical characteristics of the M-to-M cohort (n=848) according to this embodiment are shown in Table 3 below:
[0107] [Table 3]
[0108] Table 4 below shows the results of a multivariate analysis of the cumulative risk of developing cGVHD in the M-to-M cohort (n=848).
[0109] [Table 4]
[0110] Thus, the M-to-M cohort had a lower cumulative incidence of cGVHD compared with the F-to-M cohort.
[0111] Figure 3 shows the cumulative incidence of cGVHD in male recipients according to donor sex. Darker colors indicate male donors (M-to-M cohort) and lighter colors indicate female donors (F-to-M cohort). The horizontal axis indicates years since transplantation, and the vertical axis indicates the cumulative incidence of cGVHD. Specifically, at 1 year, the incidence was 35.7% (95% CI 32.4%-38.9%) vs. 48.4% (95% CI 44.8%-51.9%), P < 0.001. In other words, it was confirmed that donor gender is a risk factor for cGVHD in male recipients.
[0112] Figure 4 shows the cumulative incidence of cGVHD by HLA-DR allele in the M-to-M cohort. In the M-to-M cohort, no HLA-DR allele type was a risk factor.
[0113] Next, the clinical characteristics of the F-to-F cohort (n=615) according to this embodiment are shown in Table 5 below:
[0114] [Table 5]
[0115] Table 6 below shows the results of a multivariate analysis of the cumulative risk of developing cGVHD in the F-to-F cohort (n=615).
[0116] [Table 6]
[0117] HLA-DR alleles did not influence the incidence of cGVHD in the F-to-F cohort, i.e., no type of HLA-DR allele was a risk factor in the F-to-F cohort.
[0118] Next, the clinical characteristics of the M-to-F cohort (n=658) according to this embodiment are shown in Table 7 below:
[0119] [Table 7]
[0120] Table 8 below shows the results of a multivariate analysis of the cumulative risk of developing cGVHD by M-to-F cohort (n=658).
[0121] [Table 8]
[0122] In the M-to-F cohort, HLA-DRB1*08:03 reduced the risk of cGVHD (HR 0.66, 95% CI 0.46-0.96, P = 0.031). Additionally, HLA-DRB1*11:01 increased the risk of cGVHD (HR 1.74, 95% CI 1.02-2.98, P=0.044).
[0123] Taking these findings together, it was shown that in F-to-M HCT, HLA-DRB1*15:02, HLA-DRB1*09:01, and HLA-DRB1*12:01 are specifically associated with the development of cGVHD and predispose to the disease. Furthermore, the association between HLA-DR alleles and cGVHD was not limited to F-to-M HCT: in M-to-F HCT, HLA-DRB1*11:01 was shown to predispose to cGVHD, whereas HLA-DRB1*08:03 was shown to prevent cGVHD. In other words, certain HLA class II was associated with the development of cGVHD in F-to-M HCT and M-to-F HCT.
[0124] (The full-length DBY protein in cells forms a complex with HLA class II molecules and is presented on the cell surface.) Next, we investigated whether the HLA-DRB1*15:02 molecule, which is specifically associated with cGVHD, plays an essential role in transporting the full-length HY antigen to the cell surface. Specifically, the HY antigen is an intracellular protein, and it was unclear whether the HY antigen is expressed on the cell surface and is involved in the onset of cGVHD, so this was clarified.
[0125] FIG. 5 shows the results of FACS. Specifically, the cell surface and intracellular expression of HY antigens (DBY, EIF1AY, RPS4Y, UTY, and ZFY) was measured by flow cytometry. Mock (shaded histogram), HY antigen (dark line), or HY antigen with HLA-DRB1*15:02 (light line) was transfected into 293T cells. All HY antigens were fused with a FLAG tag at the N-terminus and detected with an anti-FLAG tag antibody. The analysis results of the cell surface (upper five histograms) and intracellular (lower five histograms) are shown.
[0126] 6 shows the results of flow cytometry measurement of HLA-DR expression. Mock (gray histogram), DBY (dark line), or DBY carrying HLA-DRB1*15:02 (light line) was transfected into 293T cells, and the transfected cells were stained with an anti-HLA-DR antibody.
[0127] As a result, when 293T cells into which HLA-DRB1*15:02 (α chain: DRA1*01:01) had been introduced were transfected with each HY antigen tagged with a FLAG tag at the N-terminus, HLA-DRB1*15:02 played an essential role in transporting the HY antigen to the cell surface. Specifically, when HY antigens were transfected alone, none of the antigens were detectable on the cell surface, whereas co-transfection with HLA-DRB1*15:02 resulted in the presence of all HY antigens on the cell surface, with DBY being the most highly expressed.
[0128] Thus, by introducing HLA class II genes, HY antigens were expressed on the cell surface, and among these HY antigens, DBY was the most expressed. Evidence indicates that plasma DBY antibodies are the strongest predictor of the development and severity of cGVHD, and therefore DBY has the greatest potential to explain why certain HLA class II alleles are associated with the development of cGVHD. In addition, since DBY has three alternatively spliced isoforms, we measured each of them and obtained similar results. Of these, we used DBY isoform 1 in subsequent experiments.
[0129] Figure 7 shows the results of co-immunoprecipitation analysis to determine whether full-length DBY forms a complex with HLA class II molecules. To detect full-length DBY, DBY was fused with a FLAG tag at the N-terminus and a Myc tag at the C-terminus. By performing IP with HLA-DR using both anti-FLAG-tag and anti-Myc-tag antibodies from cells transfected with both DBY and HLA-DR, it became possible to detect the full-length 73 kDa DBY protein. Specifically, FLAG-DBY-Myc and HLA-DRB1*15:02, FLAG-DBY-Myc, HLA-DRB1*15:02, or mock were transfected into 293T cells. The transfected cells were lysed and co-immunoprecipitation was performed using anti-HLA-DR antibody (left) and anti-FLAG-tag antibody (right). The obtained immunoprecipitates (immunoprecipitates, IP) were blotted with the indicated antibodies.
[0130] As a result, full-length DBY formed a complex with HLA class II, i.e., HLA class II molecules transported DBY protein to the cell surface without fragmenting it into peptides.
[0131] Here, we confirmed the expression of HLA-DR and Myc-tag DBY in transfected cells. To further confirm the colocalization of full-length DBY and HLA class II, IF staining was performed using anti-HLA-DR and anti-Myc-tag antibodies (Figure 8). The original magnification of each photograph is ×200, and the scale bar is 5 μm. Specifically, IF was performed on 293T cells transfected with DBY and HLA-DRB1*15:02. DBY was fused to a Myc-tag at the C-terminus and detected using an anti-Myc-tag antibody (top left). Double immunostaining of HLA-DR and Myc-tag was performed (bottom left). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI), a fluorescent dye that binds to DNA (top right). A merge of these photographs is shown in the bottom right.
[0132] Next, PLA was performed to observe protein-protein interactions. Figure 9 shows an example of PLA to visualize protein-protein interactions between Myc-tagged DBY and HLA-DR. Original magnification of each picture is 400x, scale bar is 20 μm.
[0133] Colocalization of Myc-tagged DBY and HLA-DR induced a PLA signal (light). 293T cells were mock (left) or transfected with HLA-DRB1*15:02 (right) and analyzed. Nuclei were stained with DAPI. PLA signals are detected when two antigens are closer than 40 nm, and as a result, PLA signals were detected in cells transfected with DBY and HLA-DR.
[0134] The invariant chain (Ii) acts as a chaperone for newly synthesized HLA class II molecules, preventing the loading of peptides and misfolded proteins into the endoplasmic reticulum and directing HLA class II molecules to endosomes.
[0135] Figure 10 shows the results of flow cytometry of cell surface DBY expression in the presence or absence of Ii. Mock (gray histogram), DBY and Ii with HLA class II (dark line), or DBY with HLA class II (light line) were transfected into 293T cells. Analysis results of HLA-DRB1*15:02 (left), HLA-DRB1*15:01 (middle), and HLA-DQB1*05:01 (right) are shown. Mock is pSI vector only. All data are representative of three independent experiments.
[0136] As a result, HLA-DRB1*15:02 efficiently transported DBY to the cell surface even in the presence of Ii. Similar results were observed with HLA-DRB1*15:01 and HLA-DQB1*05:01, which have been reported to present DBY peptides to CD4+ T cells (not shown).
[0137] Taken together, these findings suggest that HY antigens are expressed on the cell surface in complexes with HLA class II (HLA-DRB1*15:02), and among these HY antigens, DBY was the most frequently complexed with HLA-DRB1*15:02. In other words, it was shown that the full-length HY antigen, especially DBY, appears on the cell surface by forming a complex with HLA-DRB1*15:02, and that the affinity of DBY for HLA class II molecules is stronger than the affinity of Ii for HLA class II molecules. Hereinafter, the complex formed by binding the DBY protein and the HLA class II molecule will be abbreviated as "DBY / HLA class II complex."
[0138] (Are anti-DBY / HLA class II complex antibodies involved in the development of cGVHD?) The presence of autoantibodies against DBY in complex with HLA class II molecules is thought to increase the risk of cGVHD, i.e., the appearance of anti-DBY antibodies is associated with the development of cGVHD. However, it was unclear whether the DBY / HLA class II complex was the target antigen for cGVHD. Therefore, we investigated whether antibodies that recognize the DBY / HLA class II complex could be the cause of cGVHD.
[0139] Here, we investigated whether patients who developed cGVHD after F-to-M HCT had IgG antibodies against DBY complexed with HLA class II molecules. Because transplant patients are at risk of acquiring anti-HLA antibodies through blood transfusion, we compared plasma IgG against DBY. Specifically, we compared plasma IgG against the DBY / HLA-DRB1*15:02 complex and HLA-DRB1*15:02 alone expressed on the surface of 293T cells.
[0140] FIG. 11 shows the results of detection of anti-DBY / HLA class II complex antibodies in the plasma of patients (n=73) after F-to-M transplantation using FACS. That is, the flow cytometry results of plasma antibodies binding to DBY complexed with HLA class II molecules in patients after F-to-M HCT are shown. Here, diluted plasma was incubated with 293T cells transfected with Mock (shaded histogram), HLA-DRB1*15:02 (dark line), or DBY and HLA-DRB1*15:02 (light line). Binding of IgG antibodies to the transfected cells was evaluated by staining with anti-human IgG antibodies. Patients 1 to 6 shown in the top six histograms did not develop cGVHD. On the other hand, patients 7 to 12 shown in the bottom six histograms developed cGVHD after F-to-M HCT.
[0141] As a result, IgG antibodies against HLA-DRB1*15:02 alone were observed in some patients, regardless of whether they had developed cGVHD, whereas IgG antibodies against the DBY / HLA-DRB1*15:02 complex were detected in some cGVHD cases.
[0142] Furthermore, in patients who developed cGVHD, the mean fluorescence intensity (MFI) of plasma IgG antibodies against the DBY / HLA-DRB1*15:02 complex was higher than that against HLA-DRB1*15:02 alone. This suggests the presence of specific antibodies against the DBY / HLA class II complex in cGVHD.
[0143] We next examined whether the appearance of antibodies against the DBY / HLA class II complex increases the risk of cGVHD. Specifically, we calculated the antibody titer against the DBY / HLA class II complex by subtracting the MFI of IgG binding to GFP-positive cells transfected with HLA-DRB1*15:02 alone from the MFI of IgG binding to GFP-positive cells transfected with both DBY and HLA-DRB1*15:02.
[0144] Figure 12 shows the results of comparing the titers (antibody titers) of 143 plasma samples collected at Jichi Medical University Hospital, including 73 patients who underwent F-to-M HCT, analyzed 3 months after transplantation, with the 95% value of non-F-to-M transplant cases set as the cutoff value. Specifically, a comparison was made between the titers of anti-DBY / HLA class II complex antibodies 3 months after HCT between F-to-M and other HCTs (M-to-M, M-to-F, F-to-F). The cutoff value was determined as the 95% value of MFI in patients excluding F-to-M HCT. The dashed line indicates the MFI cutoff value. Patients who underwent M-to-M, M-to-F, and F-to-F HCT are shown on the left, and patients who underwent F-to-M HCT are shown on the right.
[0145] As a result, when the cutoff value for anti-DBY / HLA class II complex antibodies was set at 95% of MFI in patients excluding F-to-M HCT, 32 (43.8%) were identified as positive after F-to-M HCT.
[0146] Figure 13 shows the cumulative incidence of cGVHD after F-to-M HCT according to the presence or absence of anti-DBY / HLA class II complex antibodies. Gray's test was used to compare the anti-DBY / HLA class II complex antibody-positive group (light line) and the anti-DBY / HLA class II complex antibody-negative group (dark line). Of note, the cumulative incidence of cGVHD in patients who were positive for anti-DBY / HLA class II complex antibodies was higher than that in patients who were negative for antibodies: 68.8% (95% CI 48.8-82.2%) vs. 31.7% (95% CI 17.5-46.9%) at 1 year, P = 0.002.
[0147] In other words, the incidence of cGVHD was higher in cases with antibodies to the complex. Therefore, it was shown that the presence of DBY / HLA class II complex antibodies may be a risk factor for the development of cGVHD in F-to-MHCT.
[0148] Next, the positivity rate of anti-DBY / HLA class II complex antibodies was compared with the positivity rate of anti-DBY antibodies within the same cohort. Figure 14 shows the relationship between the titer of anti-DBY / HLA class II complex antibodies and the titer of anti-DBY antibodies. In other words, this is the result of detecting antibodies that only recognize DBY by indirect ELISA. The cutoff values were determined at 95% of the MFI and optical density (OD) values, except for F-to-M HCT. The dashed lines indicate the cutoff values of MFI and OD values. Circles indicate individuals. Mock is the pSI vector.
[0149] As a result, 18 of 73 patients (24.7%) had both anti-DBY / HLA class II complex and anti-DBY antibodies, but 14 patients (19.1%) had only anti-DBY / HLA complex antibodies, most of whom later developed cGVHD. This suggests that the DBY / HLA class II complex has its own alloantigen epitope in addition to the epitope shared with plate-bound DBY, i.e., antibodies against the DBY / HLA class II complex were not limited to those that simply recognize DBY.
[0150] In summary, the appearance of anti-DBY / HLA class II complexes is a risk factor for the development of cGVHD. In other words, after F-to-M transplantation, anti-DBY / HLA class II complex antibodies appeared in approximately 40% of cases. In addition, cases with anti-DBY / HLA class II complex antibodies had a higher incidence of cGVHD. Therefore, the DBY / HLA class II complex was suggested to be a target antigen for cGVHD.
[0151] (HLA class II, which is prone to forming complexes with HY antigens and HLA class II molecules, is a risk factor for cGVHD.) As mentioned above, antibodies against the DBY / HLA class II complex were involved in the development of cGVHD. However, the effect of the amount of DBY / HLA class II complex formation on the development of cGVHD is unknown. Therefore, we investigated whether the difference in the type of HLA class II allele affects the recognition of alloantibodies to DBY / HLA class II complexes. In other words, we aimed to clarify whether the formation of DBY / HLA class II complexes is HLA class II allele-dependent.
[0152] First, 22 HLA-DRB1 alleles (α chain: DRA1*01:01) were selected from five or more patients in the F-to-M cohort, and each was transfected into 293T cells to introduce DBY.
[0153] Figures 15 and 16 show the results of the analysis of DBY / HLA class II complexes for each HLA-DRB1 allele. Specifically, the HLA class II alleles show the expression levels of HLA-DR and DBY / HLA class II complexes (amount of complex formed). Different HLA-DRB1 alleles and DBY were transfected into 293T cells and analyzed by flow cytometry. The bar graphs in Figure 15 show the fluorescence values (Mean Fluorescence Intensity, MFI) of each HLA-DR and in Figure 16 show the fluorescence values (Mean Fluorescence Intensity, MFI) of DBY complexed with HLA class II molecules. MFI is shown as the mean ± standard deviation (SD) of three independent experiments.
[0154] The cell surface expression levels of HLA-DR alleles, as measured by MFI, were similar to each other, but the cell surface expression levels of DBY varied significantly among HLA-DR alleles, with HLA-DRB1*15:02 inducing DBY expression the most. Differences in HLA-DRB1 alleles influenced DBY / HLA class II complex formation and the reactivity of alloantibodies from cGVHD patients to DBY / HLA class II complexes.
[0155] In addition, the binding affinity of HLA-DRB1 alleles to DBY epitopes was analyzed using NetMHCIIpan 4.0, which defines strong binding epitopes with a %rank of 1% or less.
[0156] The results are shown in Figure 17. For each allele, the % rank for the indicated epitope is shown. It was predicted that the binding strength between HLA-DRB1*15:02 and the DBY peptide was the highest.
[0157] We also measured the affinity of alloantibodies in plasma from cGVHD patients to the DBY / HLA class II complex.
[0158] 18 shows the MFI for anti-DBY / HLA class II complex antibodies. MFI is shown as the mean ± SD of three independent experiments.
[0159] Figure 19 shows the relationship between DBY / HLA class II complex formation and the affinity of alloantibodies in plasma from cGVHD patients that bind to DBY / HLA class II complexes. Specifically, Pearson's correlation coefficient was calculated between the MFI of the two groups. R represents the correlation coefficient. Circles represent individual HLA-DRB1 alleles. HLA-DRB1*09:01, HLA-DRB1*12:01, and HLA-DRB1*15:02 are shown in light colors, respectively.
[0160] Results showed that HLA-DRB1*15:02 had the strongest binding epitope. Furthermore, the reactivity of alloantibodies from cGVHD patients to DBY / HLA class II complexes was also influenced by HLA-DR alleles, and this reactivity correlated with the surface expression level of DBY. The correlation coefficient was r=0.702 (95% CI, 0.398-0.867), P<0.001.
[0161] Notably, DRB1*15:02 exhibited both high complex formation and binding affinity, i.e., alloantibodies from cGVHD patients had the highest binding affinity to DBY complexed with HLA-DRB1*15:02, increasing the risk of cGVHD.
[0162] On the other hand, DRB1*09:01 and DRB1*12:01 had the lowest complex formation and binding affinity. In other words, HLA-DRB1*09:01 and HLA-DRB1*12:01 induced the lowest expression of DBY and were least recognized by alloantibodies, which may reduce the risk of cGVHD.
[0163] Although other HY antigens also formed complexes with various HLA-DR alleles, their surface expression levels were lower than DBY, and neither the highest nor the lowest expression of HY antigens was associated with HLA-DRB1*15:02, HLA-DRB1*09:01, or HLA-DRB1*12:01.
[0164] These results indicated that the formation of DBY / HLA class II complexes on the cell surface underlies the susceptibility to cGVHD conferred by HLA-DR alleles and directly influences the development of cGVHD. Thus, the formation of DBY / HLA class II complexes was important in the pathogenesis of chronic GVHD.
[0165] In summary, the formation of DBY / HLA class II complexes was dependent on the HLA class II allele, with the most complex formation occurring in HLA-DRB1*15:02. Furthermore, HLA-DRB1*15:02 was a risk factor allele for the development of cGVHD. On the other hand, HLA-DRB1*09:01 and HLA-DRB1*12:01 had low levels of DBY / HLA class II complex formation and a low incidence of chronic GVHD.
[0166] (Where does the DBY / HLA class II complex appear in cGVHD?) As mentioned above, the DBY / HLA class II complex has been implicated in the pathogenesis of chronic GVHD. Although DBY is widely transcribed, its translation is usually restricted to the testis, which is not one of the major target organs for cGVHD. Considering the important role of the DBY / HLA class II complex in the pathogenesis of cGVHD, we therefore investigated whether the DBY / HLA class II complex is expressed in affected organs, i.e., which sites in target tissues are expressed and targeted by the DBY / HLA class II complex.
[0167] First, we analyzed the expression of DBY and HLA class II using immunohistochemistry. Here, skin biopsy specimens with lichen planus-like histological features of cGVHD were obtained from patients (n = 4) with cGVHD after F-to-M HCT.
[0168] A representative hematoxylin-eosin (HE) stained image of this skin biopsy sample is shown in Figure 20. The scale bar in the photograph is 200 μm, and the magnification is 40x. Hyperkeratosis, acanthosis, infiltration of inflammatory cells into the subepidermis, and inflammation between the epidermis and dermis were observed.
[0169] Next, immunohistochemistry (IHC) was performed.
[0170] Figure 21 shows representative IHC results of DBY and HLA-DR in female cGVHD patients (Female, n=3; hereinafter, simply referred to as "female patients") and male cGVHD patients who underwent F-to-M HCT (F-to-M, n=4; hereinafter, simply referred to as "male patients"). The scale bar is 50 μm, and the magnification is 200 times.
[0171] As a result, DBY was expressed mainly in vascular endothelial cells in the dermis of male patients, and HLA-DR was expressed in vascular endothelial cells regardless of gender. Thus, the complex between DBY and HLA class II molecules was expressed in dermal vascular endothelial cells in the tissue (skin) of patients with cGVHD.
[0172] Interestingly, HLA class II (HLA-DR) was also expressed on vascular endothelial cells in the skin of female patients. The above-mentioned analysis using NetMHCIIpan 4.0 showed that the epitope of the anti-DBY antibody does not contain peptides that bind to HLA class II molecules, suggesting that the antibody recognizes a region outside the HLA binding site.
[0173] Next, we used PLA to examine whether DBY colocalized with HLA class II molecules.
[0174] Figure 22 shows the results of PLA to visualize protein-protein interactions of DBY and HLA-DR in cGVHD. Photomicrographs (Phase contrast) and PLA signals of a female patient (Female) and a male patient (F-to-M) are shown. Nuclei were stained with DAPI. Scale bar is 20 μm, magnification is 400x. As a result, colocalization of DBY and HLA-DR induced PLA signals in vascular endothelial cells in male patients (F-to-M), as shown by oval dots in the photograph.
[0175] Figure 23 shows the bar graph of the PLA signal. Specifically, the PLA signal per vessel from the skin of female patients (Female, n=9) and male patients (F-to-M, n=12) is shown. Data are shown as mean ± SD. P values were calculated using Student's t-test. "*" indicates P<0.05.
[0176] As a result, PLA signals were observed between DBY and HLA class II molecules in vascular endothelial cells of male patients after F-to-M HCT (P = 0.032). These results indicate that DBY is ectopically expressed on vascular endothelial cells and forms a complex with HLA class II molecules in male patients (F-to-M). That is, DBY / HLA class II complexes were expressed on the vascular endothelium in male patients (F-to-M).
[0177] Next, to further verify the importance of vascular endothelial cells as a target of cGVHD, we performed IHC staining for cGVHD biomarkers. As a biomarker for cGVHD, we first used serum B cell activating factor (B cell activating factor belonging to the TNF family, hereafter referred to as "BAFF"). BAFF is a potent B cell growth factor that is elevated in cGVHD patients and is known to correlate with the severity of the disease. Furthermore, in a cGVHD mouse model, it has been shown that fibroblast reticular cells are the main producers of BAFF. In addition, CXCL9 and CXCL10 are cytokines that are members of the CxC chemokine family and are secreted by various cells.
[0178] Figure 24 shows representative IHC staining results of BAFF in skin biopsy samples from healthy donors (n=2) and cGVHD patients (n=7). Scale bar is 50 μm, magnification is 200x. In both cases, BAFF immunoreactivity was observed by IHC in dermal vascular endothelial cells of cGVHD patients, regardless of the gender of the donor or recipient.
[0179] Next, we used CXCL9 and CXCL10 as alternative cGVHD biomarkers. CXCL9 and CXCL10 are T-helper type 1-associated inflammatory chemokines for CXCR3 and are correlated with cGVHD diagnosis and severity.
[0180] Figure 25 shows representative IHC staining results for CXCL9 and CXCL10 in skin biopsy samples from the same patient as in Figure 24. Scale bar, 50 μm, magnification, 200x. We detected staining of CXCL9 and CXCL10 on vascular endothelial cells in cGVHD skin samples. In other words, immunoreactivity of cGVHD markers was observed in IHC of dermal vascular endothelial cells of cGVHD patients, regardless of the gender of the donor or recipient.
[0181] Figure 26 shows representative results of IF of vascular endothelial marker CD31 and myofibroblast marker α-smooth muscle actin (hereinafter referred to as "αSMA") in skin biopsy samples from healthy donors (n=2) and cGVHD patients (n=7). The scale bar is 50 μm and the magnification is 200 times. Compared with healthy skin samples, cGVHD samples had increased expression of the myofibroblast marker αSMA around the dermal vascular endothelium, indicating activation of perivascular myofibroblasts and the development of tissue fibrosis. These findings highlight the potential of vascular endothelial cells as a target in cGVHD.
[0182] Next, we analyzed whether alloantibodies against the DBY / HLA class II complex exhibit cytotoxicity against cells expressing the DBY / HLA class II complex. Figure 27 shows representative results of IF of C4d, a classical complement pathway marker, in skin biopsy samples from cGVHD patients (n=7). Nuclei were stained with DAPI. Scale bar, 50 μm; magnification, 200x. As a result, C4d, a marker of the classical complement pathway, was localized to vascular endothelial cells in cGVHD skin samples.
[0183] Next, DBY and HLA-DRB1*15:02, HLA-DRB1*09:01, or HLA-DRB1*12:01 were transfected into 293T cells, and it was analyzed whether autoantibodies against the DBY / HLA class II complex promote complement-dependent cellular cytotoxicity (CDC).
[0184] Figure 28 shows the results of CDC analysis using anti-DBY / HLA class II complex antibodies. Purified total IgG from cGVHD plasma containing anti-DBY / HLA class II complex antibodies was incubated with complement in the following order: Mock, DBY, HLA-DRB1*09:01, HLA-DRB1*12:01, HLA-DRB1*15:02, DBY and HLA-DRB1*09:01, DBY and HLA-DRB1*12:01, and DBY and HLA-DRB1*15:02, and then mixed with transfected 293T cells. Dead cells were evaluated by flow cytometry. Data are shown as the mean ± SD of three independent experiments. Mock was pSI vector only. As a result, complement-dependent cytotoxicity occurred depending on the expression level of the DBY / HLA class II complex. Specifically, the number of dead cells increased in cells expressing the DBY / HLA-DRB1*15:02 complex, but not in cells expressing the DBY / HLA-DRB1*09:01 or DBY / HLA-DRB1*12:01 complex. Cells expressing only HLA class II molecules did not die.
[0185] In summary, DBY / HLA class II complexes were expressed in the vascular endothelium of skin lesions of cGVHD. In fact, cGVHD-associated markers were expressed in the vascular endothelium. Furthermore, BAFF was expressed in the vascular endothelium, which is thought to be related to B cell activation. As a result, complement-dependent cytotoxicity occurred in the vascular endothelium, suggesting that the vascular endothelium is the target tissue of cGVHD.
[0186] (The DBY / HLA class II complex is a common antigen for cGVHD and the GVL effect.) DBY complexed with HLA class II molecules is also expressed on some leukemic cells. The appearance of anti-HY antibodies reduces the risk of recurrence of hematopoietic malignancies and is associated with graft-versus leukemia (GVL). To investigate whether leukemia cells express DBY / HLA class II complexes and can serve as a common antigen for GVL, we used PLA to examine whether leukemia cells express DBY in complex with HLA class II molecules.
[0187] Figure 29 shows the results of flow cytometry analysis of HLA-DR expression in leukemia cell lines HEL, KasumiA-541, KHM-2B, KO52, Raji, and THP-1 cells. Each cell was stained with an isotype control (shaded histogram) and an anti-HLA-DR (light line) antibody.
[0188] Figure 30 shows the results of qRT-PCR analysis of DBY mRNA expression in leukemia cell lines HEL, KasumiA-541, KHM-2B, KO52, Raji, and THP-1 cells. Bar graphs show DBY mRNA expression relative to control GAPDH mRNA expression. DBY mRNA expression is shown as the mean ± SD of three independent experiments. As a result, similar expression levels of DBY were detected in KasumiA-541, KHM-2B, KO52, Raji, and THP-1 cells, among the HLA-DR-expressing leukemia cell lines derived from men.
[0189] Next, colocalization analysis of DBY and HLA-DR was performed using PLA. Figure 31 shows the results of visualizing colocalization of DBY and HLA-DR in leukemia cell lines by PLA. The results are shown for leukemia cell lines KO52 (left) and THP-1 (right). The scale bar is 20 μm, and the magnification is 400 times. As a result, small, dot-like PLA signals were induced by the colocalization of DBY and HLA-DR. That is, in the male leukemia cell lines KO52 and THP-1, DBY colocalized with HLA class II molecules in leukemia cells. However, HEL, KasumiA-541, KHM-2B, or Raji cells did not show PLA signals between DBY and HLA class II molecules.
[0190] Next, colocalization analysis of DBY and HLA-DR using PLA was performed on frozen BM samples from 14 actual male leukemia patients diagnosed between May 2021 and April 2022 at the Jichi Medical University Hospital, where the present inventor is affiliated. The background of these patients is shown in Table 9 below.
[0191] [Table 9]
[0192] In Table 9, "Blasts (%)" indicates the percentage of blast cells in the bone marrow. "HLA-DR" expression was analyzed by flow cytometry. "PLA signals" shows the results of using PLA to visualize the colocalization of DBY and HLA-DR. As described below, the colocalization of DBY and HLA-DR produced PLA signals. None of the patients had loss of the Y chromosome in their leukemic cells.
[0193] Next, we observed PLA signals from 7 of 12 patients who showed surface expression of HLA-DR on leukemic cells. In Figure 32, mononuclear cells cryopreserved from the BM of leukemia patients at the time of diagnosis were used for PLA. Patient 1 and Patient 2 were diagnosed with HLA-DR positive acute myeloid leukemia (AML). The top two micrographs are Wright-Giemsa staining, and the bottom two fluorescent micrographs are the results of PLA. Nuclei were stained with DAPI. The scale bar is 20 μm, and the magnification is 400x. Thus, in seven cases of actual leukemic cells, DBY and HLA-DR were colocalized.
[0194] Taken together, these results suggest that DBY in complex with HLA class II molecules may be a common target for cGVHD and GVL effects. Specifically, DBY / HLA class II complexes were formed in some male leukemia cell lines, KO52 and THP-1. In addition, in actual male leukemia samples, DBY / HLA class II complexes were formed in approximately half of the cases. Therefore, it is possible that the DBY / HLA class II complex may be a common antigen for GVHD and GVL.
[0195] [Conclusion] Database analysis identified HLA-DRB1*15:02 as a risk factor for cGVHD in F-to-M transplants. DBY and HLA class II formed a complex in their full length. Patients with antibodies that recognized the complex had a high incidence of cGVHD, suggesting that the DBY / HLA class II complex is a target antigen for chronic GVHD. The formation of DBY / HLA class II complexes was dependent on HLA class II, with the highest formation level being HLA-DRB1*15:02, and complex formation was directly linked to the onset of cGVHD. In actual skin lesions, the complex was expressed in the vascular endothelium, suggesting that the target site of cGVHD is the vascular endothelium, where complement-dependent cytotoxicity occurs. The DBY / HLA class II complex is expressed in leukemic cells and may be a common antigen for cGVHD and GVL effects.
[0196] Specifically, in this study, we analyzed patient groups stratified by donor-recipient sex and found that HLA-DRB1*15:02 significantly influenced the risk of cGVHD in the F-to-M cohort. In the M-to-F cohort, we also showed that HLA-DRB1*08:03 and HLA-DRB1*11:01 were associated with cGVHD, suggesting that the formation of auto- or allo-antigen / HLA class II complexes is not limited to F-to-M HCT. Supporting this finding, HLA class II expression was also observed in vascular endothelial cells of female cGVHD patients.
[0197] In fact, as mentioned above, it was revealed that among HLA-DR alleles, the one most likely to form a complex with DBY was HLA-DRB1*15:02, and the ones least likely to form a complex with DBY were HLA-DRB1*09:01 and HLA-DRB1*12:01. However, this tendency did not apply to the relationship between other HY antigens and HLA alleles. Analysis based on the nationwide database mentioned above revealed that all of these HLA-DR alleles are involved in the development of cGVHD, and the results showed that among the HY antigens, DBY is most strongly involved in the pathogenesis of cGVHD.
[0198] B cell abnormalities and alloantibody production are key features in the pathogenesis of cGVHD, but how and where intracellular alloantigens are ectopically expressed on the cell surface to trigger antibody-mediated responses has not been fully understood. In contrast, in this example, skin pathology of a patient who developed cGVHD after transplantation from a female donor to a male recipient was analyzed, and DBY / HLA class II complexes appeared on the vascular endothelium. This result also indicates that DBY is important in the pathogenesis of cGVHD. In other words, it was revealed that a specific HLA class II allele transports full-length DBY antigens to the vascular endothelial surface of tissues with cGVHD, induces autoantibodies, and is an important risk factor for cGVHD after F-to-M HCT. Furthermore, some leukemic cells express the DBY / HLA class II complex, suggesting that the DBY / HLA class II complex may function as a common target for cGVHD and the GVL effect.
[0199] In addition, the initial trigger by which cGVHD causes endothelial cell injury was previously unknown. In contrast, in this example, we demonstrated that DBY complexed with HLA class II molecules appears on the surface of vascular endothelial cells and serves as a target for autoantibodies. Furthermore, we found that alloantibodies from cGVHD patients exhibit CDC against cells expressing DBY complexed with cGVHD-risk HLA alleles. The involvement of complement is supported by previous studies showing that high serum C3 and C4 levels are associated with active cGVHD. Since alloantibodies against complexes of DBY proteins and HLA class II molecules were detected before the onset of cGVHD, the vascular endothelium may be the first target in the development of cGVHD. CDC may induce a decrease in microvessels. As a result, hypoxia is thought to cause fibrosis. Furthermore, endothelial cells in cGVHD expressed BAFF, CXCL9, and CXCL10, which may suggest that endothelial cells may act as antigen-presenting cells to attract and activate alloreactive B cells and induce IL-6 production, thereby inducing fibrosis.
[0200] It goes without saying that the configurations and operations of the above-described embodiments are merely examples and can be modified as appropriate without departing from the spirit and scope of the present invention. [Industrial Applicability]
[0201] INDUSTRIAL APPLICABILITY The present invention is expected to provide early diagnosis of cGVHD by detecting cGVHD-specific alloantibodies in F-to-M HCT, and is industrially applicable.
Claims
1. A sample containing a complex of an alloantigen protein and an HLA class II molecule is contacted with a detection reagent; Detecting alloantibodies in the sample that bind to the complex A method for detecting an allogeneic antibody.
2. The alloantigen protein is a DBY protein. The method for detecting an alloantibody according to claim 1.
3. The HLA class II molecule is at least one selected from the group consisting of HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR9, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13, HLA-DR14, HLA-DR15, and HLA-DR16. The method for detecting an alloantibody according to claim 2.
4. The sample is plasma or serum isolated from a subject. The method for detecting an alloantibody according to claim 1.
5. A detection step of detecting an alloantibody in the sample by the detection method according to any one of claims 1 to 4; and a testing step of testing for the possibility of developing chronic graft-versus-host disease based on the detection result of the alloantibody in the detection step, Test for chronic graft-versus-host disease 13. An inspection method comprising:
6. The detection step is a measurement step of measuring the antibody titer of the alloantibody.
6. The inspection method according to claim 5.
7. In the measurement step, the method for measuring the antibody titer of the alloantibody is flow cytometry.
7. The inspection method according to claim 6.
8. In the testing step, the measured value of the antibody titer of the alloantibody measured in the measuring step is compared with a reference value, and if the measured value is higher than the reference value, it is determined that the subject may develop chronic graft-versus-host disease; The reference value is a measured value obtained from a patient who has undergone allogeneic hematopoietic stem cell transplantation from a male donor to a male recipient, or from a female donor to a female recipient, or from a male donor to a female recipient.
7. The inspection method according to claim 6.
9. The subject is a patient who has undergone allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient.
9. The inspection method according to claim 8.
10. In transplants from female donors to male recipients, It is determined that the presence of HLA-DRB1*15:02 as the HLA class II molecule makes it easier for chronic graft-versus-host disease to develop, whereas the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes it harder for chronic graft-versus-host disease to develop.
10. The inspection method according to claim 9.
11. In transplants from male donors to female recipients, It is determined that the presence of HLA-DRB1*11:01 as the HLA class II molecule makes it easier for chronic graft-versus-host disease to develop, and the presence of HLA-DRB1*08:03 makes it harder for chronic graft-versus-host disease to develop.
9. The inspection method according to claim 8.
12. In allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient, It is determined that the presence of HLA-DRB1*15:02 as an allele of HLA class II makes chronic graft-versus-host disease more likely to develop, while the presence of HLA-DRB1*09:01 or HLA-DRB1*12:01 makes chronic graft-versus-host disease less likely to develop.
13. An inspection method comprising:
13. In allogeneic hematopoietic stem cell transplantation from a male donor to a female recipient, It is determined that the presence of HLA-DRB1*11:01 as an allele of HLA class II makes it easier for chronic graft-versus-host disease to develop, while the presence of HLA-DRB1*08:03 makes it less likely for chronic graft-versus-host disease to develop.
13. An inspection method comprising:
14. The method for detecting an alloantibody according to any one of claims 1 to 4, further comprising: A detection reagent characterized by:
15. The method for producing the detection reagent according to claim 10 A method for producing a detection reagent comprising the steps of:
16. The detection reagent according to claim 10 A kit for detecting an allogeneic antibody.
17. Targeting the complex of alloantigen protein and HLA class II molecule A pharmaceutical composition for treating leukemia.
Citation Information
Patent Citations
Method for assisting in prediction of prognosis of allogeneic hematopoietic stem cell transplantation
WO2018079499A1
